When ‘Too Advanced’ Isn’t the End: New Findings on Appendix Cancer Treatment
- 4 minutes ago
- 2 min read
Sardi A, Uzhegova K, Iugai S, et al. Outcomes of cytoreductive surgery in unfavorable appendix cancer histologies: meaningful survival with complete cytoreduction despite high peritoneal cancer index. Presented at: Advanced Cancer Therapies; February 2026; Fort Lauderdale, FL.
New Research Offers Hope for Patients with Advanced Appendix Cancer
For patients diagnosed with rare and aggressive appendix cancers, treatment decisions can often feel limited—especially when the disease has spread within the abdomen. One of the key factors doctors use to guide these decisions is something called the Peritoneal Cancer Index (PCI), a score that measures how much cancer is present.
Traditionally, a high PCI score has led many patients to be told they are not candidates for surgery. But new research suggests that this approach may need to change.
What the Study Looked At
Researchers studied patients with two aggressive types of appendix cancer:
High-grade mucinous carcinoma peritonei with signet ring cells (HGMCP-S)
Goblet cell adenocarcinoma (GCA)
These cancers are often difficult to treat, and many patients have a high tumor burden at diagnosis.
The study focused on patients who underwent a specialized treatment called cytoreductive surgery (CRS) combined with HIPEC (heated chemotherapy delivered directly into the abdomen). This approach aims to remove all visible tumors and treat any remaining cancer cells.
Key Findings
The results were encouraging:
Patients who had complete tumor removal during surgery lived significantly longer than those who did not
This survival benefit was seen even in patients with high PCI scores (≥20)
For some patients, survival more than doubled when complete cytoreduction was achieved
In other words, even when cancer is widespread, surgery can still make a meaningful difference—if all visible disease can be removed.
Why This Matters
For many patients, a high PCI score has been used as a reason to rule out surgery altogether. This study challenges that idea.
Instead, the findings suggest that:
Tumor burden alone should not automatically disqualify patients from surgery
The ability to achieve complete cytoreduction may be a more important factor
Patients may benefit from evaluation by teams with deep experience in these complex procedures
What Patients Should Know
If you or a loved one has been diagnosed with advanced appendix cancer and told surgery is not an option, this research offers an important reminder:
You may still have options.
Specialized centers that focus on peritoneal surface malignancies have the expertise to evaluate whether complete tumor removal is possible—even in complex cases.
The Importance of a Second Opinion
Because these cancers are rare and treatment decisions are complex, getting a second opinion can be critical. Another specialist may:
Reassess your eligibility for surgery
Offer additional treatment options
Provide access to experienced surgical teams
Moving Forward with Hope
While appendix cancers like HGMCP-S and GCA remain challenging, this research brings new hope. It highlights that with the right approach—and the right team—patients may have more opportunities for longer survival than previously thought.
